Sino Biopharmaceutical's Benmelstobart, combined with chemotherapy and Anlotinib, significantly prolonged progression-free survival (PFS) in advanced squamous NSCLC patients compared to Tislelizumab plus chemotherapy.
Jiangsu Hansoh's HS-20093, a B7-H3-targeted ADC, has received Breakthrough Therapy Designation from China's NMPA for extensive-stage small cell lung cancer (ES-SCLC) following first-line treatment.
A Phase II trial of benmelstobart, anlotinib, and chemotherapy showed a median progression-free survival of 14.9 months in advanced esophageal cancer patients.
A chemotherapy-free regimen of benmelstobart plus anlotinib demonstrated efficacy and low toxicity in Chinese patients with EGFR-positive advanced NSCLC who progressed after EGFR TKI therapy.
The combination of benmelstobart and anlotinib significantly improved progression-free survival (PFS) compared to sunitinib in advanced renal cell carcinoma (RCC).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.